


Physician's reference checklist for Exjade (deferasirox) ▼ dosing and biological monitoring



This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This document highlights important information about requirements for Exjade dosing, dose adjustment and biological monitoring. For complete information about Exjade dosing, dose adjustment and biological monitoring, please refer to Exjade EU-SmPC https://www.ema.europa.eu/en/documents/product-information/exjade-epar-product-information_en.pdf




*Further examples of dose calculation or adjustments are provided in the label. Note: When switching from deferasirox DT to Exjade FCT/granules, a lower dose is required. As referenced in SmPC: Due to different pharmacokinetic profiles, a 30% lower dose of EXJADE FCT/Granules is needed in comparison to the recommended dose for EXJADE DTs.


**Dose reduction can also be considered.

§Refer to the product label for other dose adjustments/interruptions for renal and hepatic abnormalities, metabolic acidosis, SCARs, hypersensitivity reactions.

FCT = Film-Coated Tablets; LIC = Liver Iron Concentration; NTDT = Non-Transfusion Dependent Thalassemia; DT = Dispersible Tablets



Novartis Oncology



Suspected Adverse Drug Reactions (side effects) and medication errors may be reported using the Medicines Authority ADR reporting form, which is available online at <http://www.medicinesauthority.gov.mt/adrportal> and sent by post or email to;

P: Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Zammit Buildings, Malta Life Sciences Park, San Gwann. SGN 3000.

E: postlicensing.medicinesauthority@gov.mt.

Healthcare Professionals may also report any adverse events associated with the use of EXJADE to Novartis Pharma Services Inc., Representative Office, Malta, by phone on +356 21222872, online on www.report.novartis.com or by e-mail at drug_safety.malta@novartis.com.

Marketing Authorization Holder: Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Ireland.

Local Representative: Novartis Pharma Services Inc., Representative Office Malta.
Tel No.: +356 21222872

For electronic copies of this Educational Material, please refer to the Malta Medicines Authority website - <http://www.medicinesauthority.gov.mt/rmm> - and download the required material with the latest date.

This educational material is a part of the conditions of the Marketing Authorisation

